In patients with type 2 diabetes, chronic kidney disease and albuminuria, is finerenone, a selective minerocorticoid receptor antagonist, effective and safe for lowering CKD progression?

被引：0
|
作者：
Lanthier, L. [1 ]
Plourde, M-E [2 ]
Cauchon, M. [3 ]
机构：
[1] Univ Sherbrooke, Dept Med Specialise, Serv Med Interne Gen, Sherbrooke, PQ, Canada
[2] Univ Sherbrooke, Dept Med Nucl & Radiobiol, Serv Radiooncol, Sherbrooke, PQ, Canada
[3] Univ Laval, Dept Med Familiale & Med Urgence, Quebec City, PQ, Canada
来源：
REVUE DE MEDECINE INTERNE | 2021年 / 42卷 / 02期
关键词：
NEPHROPATHY;
D O I：
10.1016/j.revmed.2020.12.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：144 / 145
页数：2
相关论文
共 50 条
  • [31] The prevalence of chronic kidney disease (CKD) and albuminuria in people with Type 1 and Type 2 diabetes attending a single centre
    Majeed, M. S.
    Teeling, M. T.
    Boran, G. B.
    Behan, L. A. B.
    Sherlock, M. S.
    Gibney, J. G.
    DIABETIC MEDICINE, 2018, 35 : 165 - 165
  • [32] The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
    Vasco, Maria Adelaida Escobar
    Fantaye, Samuel H.
    Raghunathan, Sapna
    Solis-Herrera, Carolina
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4135 - 4146
  • [33] FINERENONE AND CHRONIC KIDNEY DISEASE OUTCOMES IN BLACK PATIENTS WITH TYPE 2 DIABETES: A FIDELITY ANALYSIS
    Flack, John M.
    Agarwal, Rajiv
    Anker, Stefan D.
    Pitt, Bertram
    Ruilope, Luis M.
    Rossing, Peter
    Alder, Sharon
    Fried, Linda
    Jamerson, Kenneth
    Toto, Robert
    Brinker, Meike
    Farjat, Alfredo E.
    Kolkhof, Peter
    Joseph, Amer
    Bakris, George
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S20 - S20
  • [34] Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance
    Ebert, Thomas
    Anker, Stefan D.
    Ruilope, Luis M.
    Fioretto, Paola
    Fonseca, Vivian
    Umpierrez, Guillermo E.
    Birkenfeld, Andreas L.
    Lawatscheck, Robert
    Scott, Charlie
    Rohwedder, Katja
    Rossing, Peter
    DIABETES CARE, 2024, 47 (03) : 362 - 370
  • [35] BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes
    Georgianos, Panagiotis I.
    Kourtidou, Christodoula
    Divani, Maria
    Liakopoulos, Vassilios
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (02) : 127 - 130
  • [36] IMPACT OF INCLUSION OF FINERENONE IN THE BURDEN OF CHRONIC KIDNEY DISEASE (CKD) IN TYPE 2 DIABETES (T2D) IN COLOMBIA
    Lopez-Cabra, C.
    Rodriguez, A. D.
    Mayorga, Mogollon W.
    Zuluaga, J. R.
    Patino, A.
    Herran, S. E.
    Marrugo, R.
    VALUE IN HEALTH, 2023, 26 (06) : S137 - S137
  • [37] Associations of the TyG index with albuminuria and chronic kidney disease in patients with type 2 diabetes
    Li, Xiaonan
    Wang, Yuehui
    PLOS ONE, 2024, 19 (10):
  • [38] The Cost of Chronic Kidney Disease Progression in Type 2 Diabetes Patients
    Blonde, Lawrence
    Vassalotti, Joseph A.
    Pilon, Dominic
    Wynant, Willy
    Zhdanava, Maryia
    Lefebvre, Patrick
    Voelker, Jennifer
    Bailey, Robert
    Durkin, Michael
    DIABETES, 2019, 68
  • [39] Real-World Effectiveness of Finerenone in Chinese Patients with Type 2 Diabetes Mellitus (T2MD) and Chronic Kidney Disease (CKD)
    Li, Ang
    Gao, Ying
    Guo, Xiaohui
    Zhang, Junqing
    DIABETES, 2024, 73
  • [40] Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    Agarwal, Rajiv
    Filippatos, Gerasimos
    Pitt, Bertram
    Anker, Stefan D.
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Nowack, Christina
    Gebel, Martin
    Ruilope, Luis M.
    Bakris, George L.
    EUROPEAN HEART JOURNAL, 2022, 43 (06) : 474 - +
12345